Santhera Pharmaceuticals announces that Agamree (vamorolone) has been approved in the European Union (EU) for the treatment of Duchenne muscular dystrophy (DMD) in patients 4 years of age… read more.
Veoza (Veozah in the US), also known as fezolinetant, from Astellas, has been approved by the Medicines and Healthcare Products Regulatory Agency (MHRA) after receiving similar approval in… read more.
The FDA has approved eflornithine (Iwilfin, USWM, LLC) to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least… read more.
On 14 December 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product… read more.
Biogen Inc. announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommended marketing authorization for Skyclarys (omaveloxolone) for the treatment of… read more.
Arcutis Biotherapeutics, Inc. announced the FDA has approved the new drug application (NDA) for Zoryve (roflumilast) topical foam, 0.3% for the treatment of seborrheic dermatitis in individuals 9… read more.
Astellas Pharma Inc. announced the European Commission (EC) on December 7 approved Veoza (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms (VMS)… read more.
Medtronic plc announced that the FDA has approved the PulseSelect Pulsed Field Ablation (PFA) System for the treatment of both paroxysmal and persistent atrial fibrillation (AF). This is… read more.
Detailed results from SURMOUNT-4, which showed Zepbound (tirzepatide) injection achieved superior mean percent change in body weight compared to placebo in adults with obesity or overweight with weight-related… read more.
Vanda Pharmaceuticals Inc. announced that it has acquired U.S. and Canadian rights to Ponvory (ponesimod) from Actelion Pharmaceuticals Ltd. (Janssen), a Johnson & Johnson Company. Ponvory is approved… read more.
– Genentech, a member of the Roche Group announced that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra (emicizumab-kxwh)… read more.
Merck Inc., known as MSD outside of the United States and Canada, and Eisai announced that the Phase III LEAP-001 trial evaluating Keytruda, Merck’s anti-PD-1 therapy, plus Lenvima,… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
